ImCheck Therapeutics

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic

Founded 2015 France

France 57 employees Grant Total: $193.11M Biopharma, Biotechnology +3

General Information

Company Name ImCheck Therapeutics

Founded Year 2015

Location

France

Employees 57

Industries Biopharma, Biotechnology, Health Care +2

Funding Stage Grant

Social

BounceWatch is an independent company data service, not affiliated with ImCheck Therapeutics. To contact ImCheck Therapeutics, visit imchecktherapeutics.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ImCheck Therapeutics compare?

A PDF of ImCheck Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ImCheck Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

From the desk

Is ImCheck Therapeutics on your competitive set?

Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.

Book a 7-day Readout

Discover More

France Market

Market Signals All Companies

Biopharma

Industry Signals All Companies in France

ImCheck Therapeutics Alternatives

All Signals Trend Reports

About ImCheck Therapeutics

ImCheck Therapeutics, with the slogan "Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic," is focused on designing and developing a new generation of immunotherapeutic antibodies targeting butyrophilins, a novel super-family of immunomodulators. Their lead clinical-stage program ICT01 has demonstrated a mechanism of action to simultaneously modulate innate and adaptive immunity. This "first-in-class" activating antibody may produce superior clinical results compared to first-generation immune checkpoint inhibitors. Additionally, when used in combination, it can potentially overcome resistance to this group of agents. ImCheck is also evaluating antagonist antibodies as potential treatments for a range of autoimmune diseases. Founded in 2015 and headquartered in France, ImCheck benefits from the co-founder of the Marseille Immunopole cluster, Prof. Daniel Olive, a worldwide leader in γδ T cells and butyrophilins research. The company also has an expert management team and the commitment of leading US and European investors. The last investment was a €20.18M grant investment received on 29 August 2024 from France 2030. ImCheck Therapeutics operates in the Biopharma, Biotechnology, Health Care, Health and Wellness, and Life Sciences industries. With its innovative approach and strong support, ImCheck Therapeutics is poised to make a significant impact in the field of immunotherapy.

Business keywords: immunotherapy, oncology, antibody therapeutics, cancer treatment, immune checkpoint inhibitors, autoimmune diseases, immunomodulators, biopharmaceuticals, drug development, precision medicine

Services & Products

development of immunotherapeutic antibodies

immune system modulation research

clinical research in AML patients

Target Customers

patients with cancer patients with infectious diseases patients with autoimmune diseases

Funding Rounds & Investors (7)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	€20.18M	1	France 2030	29 Aug 2024
Series C	€96.00M	10	Earlybird, Kurma Partners +8	13 Jun 2022
Series B	€6.00M	1	Pureos Bioventures	15 Sep 2020
Series B	€48.00M	10	Bpifrance, IDInvest Partners +8	04 Dec 2019
Grant	€2.00M	1	Bpifrance	01 Aug 2019
Venture Round	€930.00K	1	Bpifrance	10 Oct 2017
Series A	€20.00M	5	IDInvest Partners, Kurma Partners +3	02 May 2017

Latest News

View All

Enpal secures €700M ABS facility, Lakestar calls time on generalist venture funds, and 15% of Slush... — Tech

Enpal secures €700M ABS facility, Lakestar calls time on generalist venture funds, and 15% of Slush alumni become founders

Tech Nov 23, 2025

Earlybird Health promotes two new partners as firm deepens biotech and analytics focus

Tech Oct 29, 2025

Ipsen expands oncology portfolio with €1B acquisition of French biotech ImCheck Therapeutics

Tech Oct 22, 2025

Kurma Partners raises €140 million first close of new €250 million Biofund IV

Eu-startups Oct 03, 2024

22 techbio soonicorns ready to cross the $1bn threshold

Sifted Feb 22, 2024

Healthcare sector attracts increased interest: Earlybird Health's new €173M fund

Tech Feb 14, 2024

ImCheck Therapeutics Alternatives & Competitors

View All Alternatives

ImCheck Therapeutics vs

Alloplex Biotherapeutics Inc United States

A robust cellular therapeutic platform for treating cancer.

Series A

5 employees

Biopharma, Biotechnology

Compare ImCheck Therapeutics vs Alloplex Biotherapeutics Inc

ImCheck Therapeutics vs

FineImmu

Creating future health with advanced cell therapy drugs and precision immunodiagnostic products.

Seed

Biopharma, Biotechnology

Compare ImCheck Therapeutics vs FineImmu

ImCheck Therapeutics vs

NextPoint Therapeutics, Inc.

Launching a new world of precision therapeutics through its leading scientific work on the novel B7...

38 employees

Biotechnology, Health Care

Also compare with:

Georgiamune Inc.

Biond Biologics Ltd View all alternatives

FAQ About ImCheck Therapeutics

Bringing a novel class of Butyrophilin-targeted checkpoint modulators into the clinic

ImCheck Therapeutics was founded in 2015.

ImCheck Therapeutics is headquartered in France.

ImCheck Therapeutics operates in Biopharma, Biotechnology, Health Care, Health and Wellness and Life Sciences. Its work centres on immunotherapy, oncology, antibody therapeutics and cancer treatment. Its customers include patients with cancer, patients with infectious diseases and patients with autoimmune diseases.

ImCheck Therapeutics has approximately 57 employees.

ImCheck Therapeutics has completed 7 funding rounds, raising a total of $193.11M. The latest funding stage is Grant.

ImCheck Therapeutics offers: development of immunotherapeutic antibodies, immune system modulation research, clinical research in AML patients.

Top alternatives and competitors to ImCheck Therapeutics include Alloplex Biotherapeutics Inc, FineImmu, NextPoint Therapeutics, Inc., ImmunOs Therapeutics AG, AltruBio Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

ImCheck Therapeutics and Alloplex Biotherapeutics Inc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ImCheck Therapeutics, https://bouncewatch.com/company/imcheck-therapeutics, updated 11 June 2025. When citing, please name BounceWatch and link this page.